Table 3.
Efficacy in patients in the biopsy subgroup (N = 49) treated with nadunolimab and GN classified using RECIST and iRECIST.
| Efficacy parameter (95% CI) | IL1RAP high (n = 29) | IL1RAP low (n = 20) | P value (IL1RAP high vs. low) |
|---|---|---|---|
| OS, median, months | 14.2 (10.0–28.6) | 10.6 (4.8–12.6) | 0.012 |
| PFS | 7.4 (3.7–11.0) | 5.1 (1.9–7.3) | 0.012 |
| iPFS, median, months | 7.4 (3.7–11.2) | 5.8 (2.7–7.4) | 0.105 |
| 1-year survival | 67% (46–81) | 39% (18–60) | — |
| ORR/iORR | 48% (29–67) | 30% (12–54) | 0.205 |
| DoR | 8.7 (3.7–11.8) | 5.6 (3.9–NE) | 0.074 |
| iDoR; median, months | 9.5 (3.7–11.8) | 5.6 (3.9–NE) | 0.044 |
Abbreviations: iDoR, immune duration of response; iORR, immune overall response rate; NE, not estimable.